Integrated BioPharma Q2 2026 Earnings Results & Report

Integrated BioPharma EPS Results

• Actual EPS: -$0.03
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Integrated BioPharma Revenue Results

• Actual Revenue: $11.28 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Integrated BioPharma (OTCMKTS:INBP), Inc. (OTCMKTS:INBP) is a healthcare products company engaged in the manufacture and distribution of vitamins, nutritional supplements, herbal products, and pharmaceutical products. Its activities are focused on products intended to support general health and wellness.

The company has historically served the U.S. market through a combination of proprietary products, contract manufacturing, and wholesale distribution activities. Its manufacturing capabilities have included a range of product formats, such as capsules, tablets, softgels, liquids, powders, creams, and lotions, depending on customer and product requirements.

Integrated BioPharma’s operations have included the development, production, and distribution of health-related consumer products for its own brands and other businesses. Publicly available information about its current leadership structure, product portfolio, and geographic reach is limited.